Medherant Ltd. Completes £1.5M Fundraising Round for Transdermal Drug Delivery Platform
Coventry, UK, 27th September 2016 / Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from ...
Medherant Shortlisted for ON Helix BioNewsRound 2016 Award
Medherant were recently shortlisted for the ON Helix BioNewsRound 2016 Award; an award which recognises the biotech related press releases which have had the most impact over the previous year. Medherant were selected for their press release in...
Mercia Makes Follow-on Investment in Medherant’s Novel Transdermal Technology
Henley-in-Arden, UK, 5th May 2016 / Mercia Fund Management (‘Mercia’), a leading investment business in UK innovation and wholly-owned subsidiary of Mercia Technologies PLC, has committed follow-on capital to Medherant Ltd, a University of W...
Medherant On Thomson Reuters TV
Ibuprofen Patch Heralds Side Effect Free Drug Future https://www.reuters.com/assets/iframe/yovideo?videoId=367483153 This video was published on Thomson Reuters TV on February 22, 2016. Copyright @Thomson Reuters, 2016....
Medherant’s First Ibuprofen Patch – TEPI Patch Technology
Researchers at the University of Warwick have worked with Coventry-based Medherant, a Warwick spinout company, to produce and patent the World’s first ever ibuprofen patch delivering the drug directly through skin to exactly where it is needed...
Interview with Mercia and Medherant by MedNous
Capital Start for University of Warwick Spin-Out Download article As universities have become better at organising their theoretical research into commercial propositions, intermediaries have appeared on the scene to nurture their research unti...